Carcinoma, Transitional Cell

Explore clinical trials studying Carcinoma, Transitional Cell. Study availability and eligibility vary by location and protocol.

417 public trials 125 recruiting studies

Refine in advanced search Browse all conditions

Carcinoma, Transitional Cell trial results

Active, Not Recruiting

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

NCT03212404

Conditions: Adenocarcinoma, Adenoma, Bronchial Neoplasms, +67 more
Locations: Research Site Wollongong, New South Wales, Australia

Research Site Benowa, Queensland, Australia

Research Site Buderim, Queensland, Australia

Research Site Greenslopes, Queensland, Australia

View all 48 locations

View Trial Details

Active, Not Recruiting

CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood

NCT04811846

Conditions: Carcinoma, Carcinoma, Transitional Cell, Circulating Tumor Cell, +21 more
Locations: LKH Hall in Tirol, Department of Urology and Andrology Hall in Tirol, Austria

LKH Salzburg, Department of Urology and Andrology Salzburg, Austria

View Trial Details

Active, Not Recruiting

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

NCT05620134

Conditions: Adenocarcinoma, Adnexal Diseases, Advanced Solid Tumor, +86 more
Locations: Institut Jules Bordet Brussels, Belgium

UZA Edegem, Belgium

UZ Ghent Ghent, Belgium

CHU UCL Namur - site Godinne Yvoir, Belgium

View Trial Details

Active, Not Recruiting

A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

NCT05867303

Conditions: Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +48 more
Locations: ICON Cancer Centre Wesley Auchenflower, Queensland, Australia

Southern Oncology Clinical Research Unit Bedford Park, South Australia, Australia

Cabrini Hospital Malvern Malvern, Victoria, Australia

Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China

View Trial Details

Active, Not Recruiting

BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer

NCT06462001

Conditions: Carcinoma, Carcinoma, Transitional Cell, Neoplasms, +4 more
Locations: Nottingham University Hospitals Nottingham, United Kingdom

View Trial Details

Active, Not Recruiting

Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC

NCT05200988

Conditions: Bladder Cancer, Carcinoma, Carcinoma, Transitional Cell, +14 more
Locations: Antoni van Leeuwenhoek ziekenhuis Amsterdam, Netherlands

Erasmus Medical Center Rotterdam, Netherlands

Universitair Medisch Centrum Utrecht Utrecht, Netherlands

View Trial Details

Active, Not Recruiting

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

NCT03179943

Conditions: Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +17 more
Locations: USC Norris Hospital and Clinics Los Angeles, California, United States

Johns Hopkins University School of Medicine Baltimore, Maryland, United States

Fox Chase Cancer Center Philadelphia, Pennsylvania, United States

View Trial Details

Carcinoma, Transitional Cell

Carcinoma, Transitional Cell trial results

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer

Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Related conditions